Razoxane and vindesine in advanced soft tissue sarcomas: impact on metastasis, survival and radiation response
Walter Rhomberg1, Helmut Eiter, Franz Schmid
1Department of Radiation Oncology, Academic Teaching Hospital, Feldkirch, Austria. walter.rhomberg@gmx.at
Background:
The treatment options in advanced soft tissue sarcomas (STS) are limited. In a pilot study, an antimetastatic and radiosensitizing treatment concept was explored.
Patients And Methods:
Twenty-one patients with unresectable and/or oligometastatic STS received the drugs razoxane and vindesine supported by radiotherapy and surgery. Long-term treatment was intended in metastatic disease. Forty-one patients with comparable stages of STS treated with contemporary chemotherapy served as non-randomised controls. The prognostic parameters of the groups were comparable.
Results:
In the study group, the median number of new metastases after 6 months was 0 (range, 0-40) and after 9 months likewise 0 (0-70). The corresponding numbers in the control group were 4.5 (range, 0-40) and 9 (0->100) (p<0.001). The progression-free survival at 6 months was 71% in the study group and 23% in the controls, and the median survival time from the occurrence of the first metastasis was 16 months versus 9 months. The rate of major responses under radiotherapy combined with razoxane and vindesine was 88%, and in the control group 62% (p=0.007). The combined treatment was associated with a low to moderate toxicity.
Conclusion:
The treatment combination inhibited the development of remote metastases in the majority of patients with STS and prolonged survival to some extent.
Insights
This study explored a novel treatment for advanced soft tissue sarcomas (STS), combining razoxane and vindesine with radiotherapy and surgery. The combination therapy significantly reduced new metastases and improved survival rates in patients with STS.
Area of Science:
- Oncology
- Medical Research
- Pharmacology
Background:
- Advanced soft tissue sarcomas (STS) present limited treatment options.
- A pilot study investigated an antimetastatic and radiosensitizing treatment concept for STS.
Purpose of the Study:
- To evaluate the efficacy of a combined treatment regimen including razoxane and vindesine, supported by radiotherapy and surgery.
- To assess the antimetastatic and radiosensitizing effects of this novel therapeutic approach in advanced STS patients.
Main Methods:
- Twenty-one patients with unresectable/oligometastatic STS received razoxane and vindesine with radiotherapy/surgery.
- Forty-one comparable STS patients receiving contemporary chemotherapy served as non-randomized controls.
- Prognostic parameters between the study and control groups were comparable.
Main Results:
- The study group showed a median of 0 new metastases at 6 and 9 months, versus 4.5 and 9 in controls (p<0.001).
- Progression-free survival at 6 months was 71% (study) vs. 23% (controls); median survival post-metastasis was 16 vs. 9 months.
- Major response rates were 88% (study) vs. 62% (controls) (p=0.007), with low to moderate toxicity.
Conclusions:
- The combined treatment effectively inhibited remote metastasis development in most STS patients.
- This therapeutic strategy demonstrated a survival benefit in advanced soft tissue sarcoma patients.
Related Concept Videos
02:49Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
01:03Rous Sarcoma Virus (RSV) and Cancer
RSV is a retrovirus that contains two copies of a plus-strand RNA genome. Its genome consists of four main open...
01:03Rous Sarcoma Virus (RSV) and Cancer
RSV is a retrovirus that contains two copies of a plus-strand RNA genome. Its genome consists of four main open...
02:57Targeted Cancer Therapies
There are several types of targeted therapies against specific...